Topics

Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review, H1 2019 [Report Updated:

06:46 EDT 12 Jul 2019 | BioPortfolio Reports

Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review, H1 2019


Summary


Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32 pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Steroid 17 Alpha Hydroxylase17,20 Lyase Pipeline Review, H1 2019, outlays comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32 Steroid 17alphahydroxylase/17, 20 lyase is an enzyme belonging to hydroxylase class that is encoded by CYP17A1 gene. It helps in conversion of pregnenolone and progesterone to their 17alphahydroxylated products and subsequently to dehydroepiandrosterone DHEA and androstenedione. It catalyzes both the 17alphahydroxylation and the 17, 20lyase reaction. It is involved in sexual development during fetal life and at puberty. The molecules developed by companies in PreRegistration, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Hormonal Disorders which include indications Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Breast Cancer, Metastatic Breast Cancer, Congenital Adrenal Hyperplasia Adrenogenital Syndrome, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Prostate Cancer and Prostate Cancer.


Furthermore, this report also reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30

The report reviews Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics and enlists all their major and minor projects

The report assesses Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review, H1 2019 [Report Updated:

NEXT ARTICLE

More From BioPortfolio on "Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 Pipeline Review, H1 2019 [Report Updated: "

Quick Search

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Sexual Health
The World Health Organization (WHO) definition of sexual health; "the state of physical, emotional, mental and social well-being related to sexuality; it is not merely the absence of disease, dysfunction and infirmity. Sexual health requires a posit...